全文获取类型
收费全文 | 1704697篇 |
免费 | 139380篇 |
国内免费 | 2662篇 |
专业分类
耳鼻咽喉 | 23572篇 |
儿科学 | 56734篇 |
妇产科学 | 48911篇 |
基础医学 | 242872篇 |
口腔科学 | 51055篇 |
临床医学 | 149812篇 |
内科学 | 332430篇 |
皮肤病学 | 37354篇 |
神经病学 | 140643篇 |
特种医学 | 69458篇 |
外国民族医学 | 474篇 |
外科学 | 260550篇 |
综合类 | 40195篇 |
现状与发展 | 3篇 |
一般理论 | 582篇 |
预防医学 | 128640篇 |
眼科学 | 38932篇 |
药学 | 128987篇 |
2篇 | |
中国医学 | 3040篇 |
肿瘤学 | 92493篇 |
出版年
2018年 | 17311篇 |
2016年 | 15705篇 |
2015年 | 17443篇 |
2014年 | 23291篇 |
2013年 | 36044篇 |
2012年 | 48597篇 |
2011年 | 51608篇 |
2010年 | 30173篇 |
2009年 | 27848篇 |
2008年 | 49842篇 |
2007年 | 52446篇 |
2006年 | 53044篇 |
2005年 | 51563篇 |
2004年 | 50480篇 |
2003年 | 48476篇 |
2002年 | 47526篇 |
2001年 | 79358篇 |
2000年 | 82960篇 |
1999年 | 68680篇 |
1998年 | 17844篇 |
1997年 | 16224篇 |
1996年 | 16018篇 |
1995年 | 16551篇 |
1994年 | 15591篇 |
1993年 | 14731篇 |
1992年 | 55928篇 |
1991年 | 54260篇 |
1990年 | 53011篇 |
1989年 | 51286篇 |
1988年 | 47580篇 |
1987年 | 47000篇 |
1986年 | 44634篇 |
1985年 | 43374篇 |
1984年 | 32515篇 |
1983年 | 27964篇 |
1982年 | 16576篇 |
1981年 | 14814篇 |
1980年 | 13925篇 |
1979年 | 30817篇 |
1978年 | 21383篇 |
1977年 | 18078篇 |
1976年 | 16983篇 |
1975年 | 17850篇 |
1974年 | 21775篇 |
1973年 | 20907篇 |
1972年 | 19060篇 |
1971年 | 17987篇 |
1970年 | 16495篇 |
1969年 | 15453篇 |
1968年 | 14135篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
43.
Nicholas E. Propson Ethan R. Roy Alexandra Litvinchuk Jrg Khl Hui Zheng 《The Journal of clinical investigation》2021,131(1)
Dysfunction of immune and vascular systems has been implicated in aging and Alzheimer disease; however, their interrelatedness remains poorly understood. The complement pathway is a well-established regulator of innate immunity in the brain. Here, we report robust age-dependent increases in vascular inflammation, peripheral lymphocyte infiltration, and blood-brain barrier (BBB) permeability. These phenotypes were subdued by global inactivation and by endothelial cell–specific ablation of C3ar1. Using an in vitro model of the BBB, we identified intracellular Ca2+ as a downstream effector of C3a/C3aR signaling and a functional mediator of vascular endothelial cadherin junction and barrier integrity. Endothelial C3ar1 inactivation also dampened microglia reactivity and improved hippocampal and cortical volumes in the aging brain, demonstrating a crosstalk between brain vasculature dysfunction and immune cell activation and neurodegeneration. Further, prominent C3aR-dependent vascular inflammation was also observed in a tau-transgenic mouse model. Our studies suggest that heightened C3a/C3aR signaling through endothelial cells promotes vascular inflammation and BBB dysfunction and contributes to overall neuroinflammation in aging and neurodegenerative disease. 相似文献
44.
45.
Sounak Gupta Rafael E. Jimenez Loren Herrera-Hernandez Christine M. Lohse R. Houston Thompson Stephen A. Boorjian Bradley C. Leibovich John C. Cheville 《Mayo Clinic proceedings. Mayo Clinic》2021,96(6):1470-1489
ObjectiveTo study the clinical features and identify unique renal neoplasia subtypes and their prognostic implications in individuals with tuberous sclerosis complex (TSC).Patients and MethodsThe Mayo Clinic nephrectomy registry included 37 patients with TSC diagnosed between 1970 and 2018. Four additional patients were identified from the pathology consultation and autopsy files. All available renal tumors were further characterized using immunohistochemistry and fluorescence in situ hybridization. Clinicopathologic features and follow-up were obtained from the medical record. The American Association for Cancer Research Project GENIE registry was accessed using cBioPortal for molecular profiling of angiomyolipoma (AML).ResultsA total of 276 renal tumors from 41 patients were analyzed. Renal tumors were classified into 9 distinct morphological subtypes, with AML predominating (238 [86%]). Interestingly, all these tumors acted in a benign fashion except one renal cell carcinoma with clear cells and fibromyomatous stroma and one epithelioid AML that metastasized. Molecular profiling studies revealed that epithelioid AMLs were enriched for alterations of TP53, RB1, and ATRX. Eight patients died of direct complications of TSC, including 3 of end-stage renal disease. To date, none have died of a renal epithelial neoplasm.ConclusionThe identification of unique renal neoplasia subtypes may provide important clues to establish a diagnosis of TSC, and in the somatic setting, this finding has important implications for accurate prognostication. These tumors tend to be indolent, and only 2 of 276 tumors in our study exhibited metastatic behavior. Our results support multidisciplinary management with a focus on preservation of renal function. 相似文献
46.
47.
48.
49.
50.
Rajiv V. Dave Baek Kim Alona Courtney Rachel OConnell Tim Rattay Vicky P. Taxiarchi Jamie J. Kirkham Elizabeth M. Camacho Patricia Fairbrother Nisha Sharma Christopher W. J. Cartlidge Kieran Horgan Stuart A. McIntosh Daniel R. Leff Raghavan Vidya Shelley Potter Chris Holcombe Ellen Copson Charlotte E. Coles Ramsey I. Cutress Ashu Gandhi Cliona C. Kirwan 《British journal of cancer》2021,124(11):1785
Background The B-MaP-C study aimed to determine alterations to breast cancer (BC) management during the peak transmission period of the UK COVID-19 pandemic and the potential impact of these treatment decisions.Methods This was a national cohort study of patients with early BC undergoing multidisciplinary team (MDT)-guided treatment recommendations during the pandemic, designated ‘standard’ or ‘COVID-altered’, in the preoperative, operative and post-operative setting.Findings Of 3776 patients (from 64 UK units) in the study, 2246 (59%) had ‘COVID-altered’ management. ‘Bridging’ endocrine therapy was used (n = 951) where theatre capacity was reduced. There was increasing access to COVID-19 low-risk theatres during the study period (59%). In line with national guidance, immediate breast reconstruction was avoided (n = 299). Where adjuvant chemotherapy was omitted (n = 81), the median benefit was only 3% (IQR 2–9%) using ‘NHS Predict’. There was the rapid adoption of new evidence-based hypofractionated radiotherapy (n = 781, from 46 units). Only 14 patients (1%) tested positive for SARS-CoV-2 during their treatment journey.Conclusions The majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer survival outcomes are unlikely to be negatively impacted by the pandemic. However, in this study, the potential impact of delays to BC presentation or diagnosis remains unknown.Subject terms: Breast cancer, Surgical oncology, Health care economics, Quality of life, Health policy 相似文献